- April 2, 2014
- February 19, 2014
Rares sont les sociétés de biotechnologies à avoir les reins assez solides pour racheter un candidat médicament à une « big pharma ». C'est le cas d' Innate Pharma, spécialiste de l'immuno-oncologie.
- February 16, 2014
Si la vidéo ne se lance pas directement, rendez-vous sur http://www.bfmtv.com/
- January 9, 2014
Innate Pharma's lirilumab is one of the most promising oncology products being developed. The Phase I trials run by its partner Bristol-Myers Squibb in combination with the high-profile antibodies, ipilimumab and nivolumab, are advancing as expected. Preclinical data presented at December's ASH meeting also indicated that lirilumab might be able to enhance the activity of many other oncology antibodies. Innate Pharma has just raised €20.3m, which will help it develop its pipeline. We raise our valuation to €259m.
- January 8, 2014
I often hear investors complain about the difficulty finding undiscovered and undervalued biotech stocks. With the year we've just had, many companies with compelling drugs in development also have valuations bid up, but hidden gems remain to be discovered in 2014.
- December 20, 2013
Editors of the journal Science ranked cancer immunotherapy at the top of their list of scientific achievements this past year:
"This year marks a turning point in cancer, as long-sought efforts to unleash the immune system against tumors are paying off—even if the future remains a question mark."
- December 4, 2013
Les fonds américains convoitent les pépites de la biotechnologie française
Au cours des dix derniers jours de novembre, l'action d'Innate Pharma a progressé de 75 %. Cet engouement, la société de biotechnologie française, située à Marseille et spécialisée dans l'immuno-oncologie – une approche innovante pour traiter les cancers en dopant le système immunitaire –, le doit aux bonnes fées américaines qui se sont penchées sur son berceau.
- December 2, 2013
- November 27, 2013
Jérôme Tiollier, Executive Vice President and Chief Development Officer, was at the Agora of Presidents on ACTIONARIA (November 22, 2013, Paris, France)
- November 23, 2013
Innate financing confirms importance of US to European biotechs
Innate Pharma this week became the latest European drug developer to turn to the US to seek investor support. The French immuno-oncology company raised €20.3m ($27.3m) in a private placement directed exclusively at investors across the Atlantic, sending its Paris-listed shares to a six-year high.